BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27533075)

  • 1. Eosinophilic Infiltrates in Vemurafenib-Associated Verrucous Keratoses.
    Longhurst WD; Honda K; Koon HB; Gerstenblith MR
    Am J Dermatopathol; 2016 Oct; 38(10):766-8. PubMed ID: 27533075
    [No Abstract]   [Full Text] [Related]  

  • 2. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 3. Hidradenitis suppurativa, eruptive melanocytic nevi, and keratosis pilaris-like eruption in a patient treated with vemurafenib.
    Ma L; Dominguez AR; Collins GR; Kia KF; Cockerell CJ
    Arch Dermatol; 2012 Dec; 148(12):1428-9. PubMed ID: 23247496
    [No Abstract]   [Full Text] [Related]  

  • 4. Pemetrexed-Induced Pseudocellulitis Reaction With Eosinophilic Infiltrate on Skin Biopsy.
    Tracey EH; Modi B; Micheletti RG
    Am J Dermatopathol; 2017 Jan; 39(1):e1-e2. PubMed ID: 27415636
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vemurafenib (PLX-4032)-induced keratoses: verrucous but not verrucae.
    Ko CJ; McNiff JM; Iftner A; Iftner T; Choi JN
    J Am Acad Dermatol; 2013 Aug; 69(2):e95-6. PubMed ID: 23866896
    [No Abstract]   [Full Text] [Related]  

  • 6. A Case of Perforating Folliculitis Induced by Vemurafenib.
    Shiraishi K; Masunaga T; Tohyama M; Sayama K
    Acta Derm Venereol; 2019 Feb; 99(2):230-231. PubMed ID: 30281138
    [No Abstract]   [Full Text] [Related]  

  • 7. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

  • 8. Painful nipple hyperkeratosis secondary to vemurafenib.
    Carr ES; Brown SC; Fiala KH
    Dermatol Ther; 2017 May; 30(3):. PubMed ID: 28211633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acne inversa-like skin lesions as a potential adverse event during vemurafenib therapy.
    Thiem A; Mergler R; Kneitz H; Weyandt G; Goebeler M; Gesierich A
    J Dtsch Dermatol Ges; 2016 Apr; 14(4):427-8. PubMed ID: 27027759
    [No Abstract]   [Full Text] [Related]  

  • 10. Eccrine squamous syringometaplasia associated with vemurafenib therapy.
    Story SG; Beschloss JK; Dolan CK; Thomas BC
    J Am Acad Dermatol; 2012 Nov; 67(5):e208-10. PubMed ID: 23062917
    [No Abstract]   [Full Text] [Related]  

  • 11. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 12. Histopathological features of cutaneous drug reactions to vemurafenib: a report of two cases.
    Dabner M; Harvey NT; Soma A; Wood BA
    Pathology; 2012 Dec; 44(7):661-4. PubMed ID: 23172086
    [No Abstract]   [Full Text] [Related]  

  • 13. Vemurafenib-associated keratoses with genetic heterogeneity of RAS.
    Loh E; Hosler GA
    J Drugs Dermatol; 2014 Apr; 13(4):495-7. PubMed ID: 24719071
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keratosis pilaris-like eruption observed during the experimental PLX 4032 studies.
    van der Kooi K; Glass LF; Messina JL; Trimble JS
    J Am Acad Dermatol; 2012 Dec; 67(6):e286-7. PubMed ID: 23158643
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib-induced panniculitis.
    Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
    Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
    [No Abstract]   [Full Text] [Related]  

  • 16. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor.
    Lacouture ME; Desai A; Soltani K; Petronic-Rosic V; Laumann AE; Ratain MJ; Stadler WM
    Clin Exp Dermatol; 2006 Nov; 31(6):783-5. PubMed ID: 16824050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib-induced interface dermatitis manifesting as radiation-recall and a keratosis pilaris-like eruption.
    Braunstein I; Gangadhar TC; Elenitsas R; Chu EY
    J Cutan Pathol; 2014 Jun; 41(6):539-43. PubMed ID: 24517243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous toxicities associated with vemurafenib therapy in 107 patients with BRAF V600E mutation-positive metastatic melanoma, including recognition and management of rare presentations.
    Sinha R; Larkin J; Gore M; Fearfield L
    Br J Dermatol; 2015 Oct; 173(4):1024-31. PubMed ID: 26109403
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vemurafenib-induced DRESS.
    Wenk KS; Pichard DC; Nasabzadeh T; Jang S; Venna SS
    JAMA Dermatol; 2013 Oct; 149(10):1242-3. PubMed ID: 23986488
    [No Abstract]   [Full Text] [Related]  

  • 20. A case of vemurafenib-induced keratosis pilaris-like eruption.
    Wang CM; Fleming KF; Hsu S
    Dermatol Online J; 2012 Apr; 18(4):7. PubMed ID: 22559022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.